Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone

SANDRA SOTOMAYOR1, MARÍA J. CARMENA1, ANDREW V. SCHALLY2,3, JOZSEF L. VARGA2,3, MANUEL SÁNCHEZ-CHAPADO4,5, JUAN C. PRIETO1 and ANA M. BAJO1

1Molecular Neuroendocrinology Unit, Department of Biochemistry and Molecular Biology, University of Alcalá, 28871 Alcalá de Henares, Spain; 2Veterans Administration Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL 33125; 3University of Miami, School of Medicine, Miami, FL 33136, USA; 4Department of Surgery, University of Alcalá, and 5Department of Urology, Príncipe de Asturias Hospital, 28871 Alcalá de Henares, Spain

Received May 29, 2007; Accepted July 2, 2007

Abstract. Receptors for vasoactive intestinal peptide (VIP) and the human epidermal growth factor family of tyrosine kinase receptors (HER) are potent promoters of cell proliferation, survival, migration, adhesion and differentiation in prostate cancer cell lines. In this study, we analyzed the cross-talk between both classes of receptors through the regulation of HER2 transactivation and expression by VIP. Three growth-hormone-releasing hormone analogs endowed with antagonistic activity for VIP receptors (JV-1-51, -52, and -53) abrogated the autocrine/paracrine stimuli of VIP on androgen-independent PC3 cells in the absence or the presence of 10% fetal bovine serum. Semiquantitative and real-time quantitative RT-PCR together with Western blotting showed increased expression levels of both mRNA and proteins for HER2 and HER3 in PC3 and androgen-dependent LNCaP prostate cancer cells as compared to non-neoplastic RWPE-1 cells. VIP (100 nM) stimulated the expression levels of both HER2 and HER3 in PC3 cells in a time-dependent manner.

Introduction

Prostate cancer is the second leading cause of cancer-related deaths among men in the Western world (1). It presents as a heterogeneous and multi-stage disease, both at the clinical and histological level. In spite of major improvements in diagnosis, including screening for serum prostate specific antigen (PSA), many prostate cancers are detected at an advanced stage with no possibility of cure by radical prostatectomy (2). Because approximately 70% of prostate cancers are androgen-dependent at the time of diagnosis, the preferred treatment of advanced prostate cancer is androgen ablation. However, after an initial response and a period of remission, most patients show a relapse with ultimate progression to androgen-independent prostate cancer, for which the prognosis is very poor (2,3). The mechanisms responsible for the loss of androgen dependence are not fully understood. Nevertheless, an active investigation on the role of neuropeptides, neuroendocrine cells and growth factors in the progression of prostate cancer should lead to the development of novel therapies (3,4).

Vasoactive intestinal peptide (VIP) is a pleiotropic neuropeptide that behaves as a potent vasodilator. VIP stimulates prostatic secretion, inhibits muscle contraction, and increases the proliferation of prostatic epithelial cells in culture (5). VIP is also known to increase PSA secretion (6) as well as vascular endothelial growth factor (VEGF) expression and neuroendocrine differentiation in human prostate cancer cell lines (7,8). Furthermore, this neuropeptide stimulates the invasive capacity of prostate cancer cells and protects them from apoptosis (9-11). The biological effects of VIP are mediated by two membrane receptors VPAC1 and VPAC2, which are G-protein coupled receptors (GPCRs) widely expressed in many tissues (12,13) including normal and malignant prostate gland (4,14) as well as prostate cancer cell lines (7,15). Interaction of VIP with these receptors initiates a
set of events which lead to the activation of protein kinase A (PKA) and phosphorylation of transcriptional factors for specific genes through cAMP response element binding protein (CREB), as well as the activation of the phosphoinositide 3-kinase (PI3-K) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) and MAPK kinase (MEK1/2) systems (4,9,16-18). Interestingly, VIP and growth-hormone-releasing hormone (GHRH) show structural similarity as well as considerable homology between their receptor proteins (19). Two GHRH analogs, JV-1-51 and JV-1-52, have been synthesized that present reduced antagonistic activities on GHRH receptors and increased antagonistic properties on VPAC1 and VPAC2 receptors compared with their parent compounds, as well as the potent antagonist of VPAC1 and VPAC2 receptors, JV-1-53, that is devoid of antagonistic activity on GHRH receptors (19,20). The abrogation of the autocrine/paracrine mitogenic activity of VIP by these antagonists might be of potential value for prostate cancer therapy (21).

The human epidermal growth factor receptor (ErbB/HER) family is comprised of four homologous receptors: EGFR (HER1/ErbB1), HER2/ErbB2, HER3/ErbB3 and HER4/ErbB4. These receptors are composed of an extracellular binding domain, a transmembrane lipophilic segment, and an intracellular protein tyrosine kinase (TK) domain that is absent in HER3 (22). After ligand binding, HER receptors become activated by dimerization between two identical (homodimerization) or different (heterodimerization) receptors of the same family (23,24). After receptor dimerization, activation of the intrinsic protein kinase activity and tyrosine autophosphorylation occur, recruiting and phosphorylating several intracellular substrates involving apoptosis and cellular proliferation (25,26). HER2 is a unique member of the HER family in that it does not bind any of the known ligands but it is the preferred heterodimeric partner for the other ErbB/HER receptors. The overexpression and the heterodimerization via ligand binding or non-ligand-dependent receptor dimerization, promote tumorigenesis through cell proliferation, survival, migration, adhesion and differentiation (27). Comparison of all receptor combinations revealed that heterodimerization of the ligandless HER2 with the kinase-inactive HER3 provides the most potent mitogenic and angiogenic signals (28,29). Among the members of the HER/ErbB family, HER1 and HER2, in particular play an important role in the development and progression of various tumors, including prostate cancer (30,31). Many studies have been dedicated to HER2 which activates the androgen receptor and promotes androgen-independent survival and growth of prostate cancer cells (32-35). Interestingly, it has been shown that several agonists of GPCR have the capability to transactivate EGF receptors and thereby recruit associated effector signaling pathways (36,37). In this context, VIP (a GPCR agonist) stimulates HER1 tyrosine phosphorylation through an elevation in intracellular cAMP and activation of PKA in colonic epithelial T84 cells (37).

The present study was undertaken with the main aim of determining the link between VIP receptors and HER2 by means of VIP-induced HER2 transactivation in prostate cancer. Mimicking tumor progression, non-neoplastic RWPE-1 cells as well as androgen-dependent LNCaP and independent PC3 cancer cell lines were analyzed for the expression of mRNAs for HER2 and HER3, and HER proteins. Furthermore, the more aggressive cell line, PC3, was used to study the anti-proliferative effects of VPAC receptor antagonists (JV-1-51, -52 and -53), the effect of VIP on HER2 and HER3 expression, as well as the transactivation of HER2 by VIP and its blocking by inhibition of VIP signaling. This approach was considered to be useful for the evaluation of the potential therapeutic value of VIP antagonists combined with inhibitors of HER2 signaling for treatment of advanced prostate cancer.

Materials and methods

Reagents. VIP was purchased from NeoMPS (Strasbourg, France). Chemicals for sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), and monoclonal anti-ß-tubulin were obtained from Sigma (St. Louis, MO) and ß-actin was purchased from Calbiochem (Darmstadt, Germany). Protein markers for SDS-PAGE were from Bio-Rad (Hercules, CA, USA). The antisera specific for HER2 and HER3 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and that for phospho-HER2-Tyr1248 (HER2-P) was acquired from Upstate (Lake Placid, NY). The synthesis of the human GHRH analogs JV-1-51, JV-1-52 and JV-1-53 was previously described (19,20).

Cell lines. Epithelial human prostate non-neoplastic (RWPE-1), androgen-dependent (LNCaP), and androgen-independent (PC3) prostate carcinoma cell lines, which exhibit different features of prostate cancer progression, were used in receptor expression analysis. Other studies were performed in PC3 cells. The three cell lines were obtained from the American Type Culture Collection (Manassas, VA). RWPE-1 cells were maintained in complete keratinocyte serum-free medium (K-SFM) containing 50 μg/ml bovine pituitary extract and 5 ng/ml EGF. LNCaP and PC-3 cells were cultured in RPMI-1640 medium (Life Technologies, Barcelona, Spain) supplemented with 1% antibiotic/antimycotic and 10% fetal bovine serum (FBS). The cells were grown at 37°C in a humidified atmosphere containing 95% air/5% carbon dioxide and split weekly with 0.25% trypsin/0.2% EDTA. All culture media components were purchased from Invitrogen (Barcelona, Spain).

Cell proliferation assay. For all experiments, PC-3 cells were grown to 70-80% confluence, harvested by use of trypsin/EDTA solution and seeded at low concentration (50,000 cells per well) in 24-well plates for 24 h. The culture medium was replaced and cultured with RPMI-1640 medium containing 1% antibiotic/antimycotic and 0% FBS for 24 h. After the deprivation, cells were stimulated for 24 h with 100 nM VIP and/or 300 nM antagonists JV-1-51, JV-1-52 or JV-1-53. Cell growth was determined by tetrazolium assay, which measures the reduction of substrate MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] to a dark blue formazan product by mitochondrial dehydrogenases in living cells. Thereafter, MTT (5 mg/ml) (Sigma) was added to each well and incubated for 3 h at 37°C in darkness. The medium was
reaction (RT-PCR). Cells (1.5x10^6 in 100-mm² cell culture dishes) were stimulated with 100 nM VIP for 15, 30, 45, and 60 min. Total RNA was extracted from cells by using TRIR reagent (Biotech Labs, Houston, TX), according to the manufacturer's instructions. Two μg of total RNA was reverse-transcribed into cDNA by M-MLV reverse transcriptase, according to the manufacturer's guidelines (Life Technologies, Barcelona, Spain). In order to rule out genomic DNA contamination the RT was also performed without reverse transcriptase. Primers were chosen with the assistance of the computer program Primer Express (Perkin-Elmer Applied Biosystems, Foster City, CA) (Table I). The number of cycles was determined in preliminary experiments to be within the exponential range of PCR amplification. Negative controls with water instead of cDNA were run in parallel to exclude genomic DNA contamination. PCR conditions were denaturation at 94°C for 5 min, followed by 94°C for 1 min, 60°C for 1 min, 72°C for 1 min by different cycles (Table I), and then a final cycle of 10 min at 72°C. PCR products were subjected to electrophoresis on a 2% agarose gel, stained with ethidium bromide and visualized under UV light. Bands of PCR-amplified products were scanned and analyzed semiquantitatively, using an Imaging System (Gel Doc™ XR, Bio-Rad, Madrid, Spain). All the experiments were repeated at least three times and similar results were obtained. The mRNA levels of HER2 and HER3 genes were normalized versus the corresponding levels of β-actin. The PCR products were purified by a gel extraction kit (Qiagen, Hilden, Germany), and sequenced by an ABI 377 sequencing machine (Applied Biosystems). The sequences were compared with the GenBank database using BLAST analysis (http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi).

**Single-step real-time quantitative RT-PCR.** Real-time quantitative RT-PCR analysis was carried out using 90 ng of RNA for each sample and SYBR-Green PCR master mix (Applied Biosystems) in one-step RT-PCR protocol according to the manufacturer's instructions. The thermal cycling conditions were constant at 50°C for 10 min and 95°C to activate MultiScribe™ reverse transcriptase, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. The PCR amplicon region for HER2 and HER3 was obtained. To define the threshold cycle number at which product is first detected by fluorescence, the amount of target (HER2 and HER3) was normalized to an endogenous reference, the housekeeping gene for β-actin. ΔCt was the difference in Ct values derived from the studied genes in each sample assayed and the β-actin gene. ΔΔCt represented the difference between the paired samples. The n-fold differential ratio was expressed as 2^ΔΔCt (38).

**Immunodetection of ErbB/HER family members.** Cells were washed once with ice-cold PBS and then scraped into ice-cold PBS. Afterwards, cells were treated with lysis buffer [25 mM Triethanolamine (pH 7.4), 150 mM NaCl, 1% (v/v) Triton X-100, 1% (v/v) Nonidet P-40 (NP-40), 30 mM NaF, 5 mM EDTA, 1 mM dithiothreitol (DTT), 0.1% SDS, 1 mM Na3VO4, 2 mM phenylmethylsulfonyl fluoride (PMSF), 10 μg aprotinin, 10 μg leupeptin, and 10 μg pepstatin]. Protein content was measured by the Bradford assay using bovine serum albumin as standard. Protein (30-60 μg) from cell lysates was solubilized in 50 mM Tris-HCl buffer (pH 6.8) containing 10% (v/v) glycerol, 3% (w/v) SDS, 0.01% bromophenol blue, and 0.7 M β-mercaptoethanol and then heated for 5 min. Proteins were resolved on a 8% SDS-PAGE and then transferred to nitrocellulose sheets (Hoeffer, San Francisco, CA). The nitrocellulose sheets were soaked in Tris-buffered saline (TBS) containing 2 mM Tris (pH 7.6) and 0.8% NaCl (or PBS for HER2-P). Excess protein-binding sites were saturated with TBS or PBS containing 0.1% Tween-20 and 5% non-fat dried milk. The blotted membranes were incubated for 2 h with rabbit polyclonal antihuman antibodies: HER2, HER3, and HER2-P at 1:500, 1:2,000, and 1:4,000, respectively. Mouse monoclonal antihuman antibodies, β-actin and β-tubulin (1:7,000 and 1:4,000, respectively), were used as loading controls. The bands were analyzed with the imaging densitometer as above, and the relative protein levels were normalized versus the corresponding levels of β-tubulin or β-actin.

**Statistical analyses.** Data are expressed as the means ± SE. Statistical analyses were performed using the Student's two-tailed t-test. All P-values are based on two-sided hypothesis testing. P<0.05 was considered to be significant.

**Results**

**Effects of VIP and VIP antagonists on proliferation in prostate cancer PC3 cells.** We studied the effects of GHRH analogs JV-1-51, -52 and -53 on the proliferation of androgen-independent PC3 that represent advanced prostate cancer (Fig. 1). In both the absence or the presence of 10% FBS,
VIP stimulated cell proliferation and the three GHRH analogs completely inhibited VIP’s effect when added 30 min before or simultaneously with the neuropeptide. When incubated alone with the cells, JV-1-51 and -52, but not JV-1-53, exhibited an antiproliferative effect in the presence of 10% FBS whereas all three peptides were ineffective in the absence of serum.

Expression of HER2 and HER3 mRNAs and proteins in prostate non-neoplastic and cancer cell lines. Prior to the study of the effect of VIP upon expression and activation of HER, we determined the levels of mRNA and protein for HER2 and HER3 throughout cancer progression. For this purpose, total RNA was extracted from non-neoplastic RWPE-1 and cancerous LNCaP and PC3 cells and subjected to both semiquantitative RT-PCR and single-step real-time quantitative RT-PCR. As shown in Fig. 2, HER2 and HER3 mRNAs were detected in the three cell lines, the levels being low in control RWPE-1 cells and increased in cancer cells, and exhibiting the highest values in androgen-dependent LNCaP cells as compared to androgen-independent PC3 cells.

Thereafter, we evaluated by means of Western blot analysis and further densitometry whether the observed mRNAs translated into the corresponding proteins (Fig. 3). Again, the levels of expression of both HER2 and HER3 as well as those of HER2-P were higher in cancer cells as compared to normal cells. In fact, only a weak signal was detected for HER2-P whereas HER2 and HER3 were undetectable in normal RWPE1 cells in the conditions of the assay. The incubation of PC3 cells with EGF resulted in a higher extent of HER2 tyrosine phosphorylation.

Effect of VIP on HER2 and HER3 expression in prostate cancer PC3 cells. The Gs PCR agonist VIP induced the expression of mRNAs for HER2 and HER3 in PC3 cells as shown by means of both semiquantitative and real-time quantitative RT-PCR (Fig. 4). The effect was time-dependent and the highest responses to 100 nM VIP were seen at 45 and 60 min of cell incubation for HER2 and HER3, respectively. The study of protein levels showed again a time-dependent stimulatory effect of VIP (Fig. 5). Cell incubation with 100 nM VIP resulted in maximal responses of HER2 and HER3 protein expression at 120 and 60 min, respectively.
HER2 transactivation by VIP in prostate cancer PC3 cells. In PC3 cells, VIP stimulated tyrosine phosphorylation of HER2 in a time-dependent fashion, as shown by cell incubation with 100 nM VIP followed by Western blotting with anti-HER2-P (Fig. 6). The effect of VIP was rapid in onset with maximal HER2 phosphorylation occurring within 30 sec after the addition of the neuropeptide. A less prominent effect was observed between 15-30 min.

VIP acts mainly through adenylate cyclase/PKA activation but also via other signaling pathways (16-18). Thus, we determined which pathway is involved in the observed HER2 transactivation (Fig. 7). The early response to VIP was mediated by neuropeptide binding to VPAC receptors since cell preincubation for 30 min with the specific antagonist JV-1-53 (300 nM) nearly suppressed early HER2 phosphorylation in response to VIP.
The present study shows that VIP can modulate HER2 signaling within androgen-independent cancer PC3 cells by at least two mechanisms, increasing HER2 expression levels as well as HER2 tyrosine phosphorylation. These observations provide a framework to characterize the potential usefulness in prostate cancer therapy of combinations of available VIP receptor antagonists (19-21) and both monoclonal antibodies and tyrosine kinase inhibitors targeted to different members of the EGFR/HER family (34,35).

Our results confirm previous data on the antimitogenic ability of some GHRH analogs endowed with VIP antagonistic activity in human prostate cancer cells (21,39). The GHRH analogs JV-1-51, -52 and -53 nullified the autocrine/paracrine mitogenic stimuli of VIP. In addition, JV-1-51 and -52 exerted a significant antiproliferative effect when incubated alone with PC3 cells in the presence of serum. This difference between JV-1-51 and -52 as compared to JV-1-53 might be due to the mixed dual antagonistic properties of the two first peptide analogs that can bind to both VIP and GHRH receptors. Thus, the effect of JV-1-51 and -52 involved possibly additive responses whereas the action of JV-1-53 would have been elicited only through VIP receptors. Similar observations have been performed in prostate cancer LNCaP cells (39).

The role of VIP in prostate cancer progression is based upon reports on cell lines and/or tissue specimens from prostatic origin showing overexpression of VPAC1 receptors (4) and reports on cell lines and/or tissue specimens from prostatic tissue and cell lines, and its overexpression appears to involve transcriptional activation more than genomic amplification (31,33,40,41). HER2 is the preferred receptor partner for HER1 and HER3 heterodimerization giving potent mitogenic signals (28,29); it activates androgen receptor and has been linked to the clinical progression of ablation-resistant human prostate cancer (32,33). Clinical trials are in progress in prostate cancer patients to test novel molecules that selectively interfere with HER2 activity (34,35,42). Our study on HER2 and HER3 expression throughout prostate cancer progression showed increased mRNA levels that correlated with augmented protein levels for both receptors as well as the phosphorylated form of HER2 in tumoral LNCaP and PC3 cells as compared to normal, non-neoplastic RWPE-1 cells, in agreement with previous observations (33,41). We used semiquantitative and real-time quantitative RT-PCR for mRNA, and Western blotting for protein measurements which did not detect any HER2 or HER3 protein in RWPE-1 cells under the conditions of the test. This finding could be explained in terms of instability of mRNAs that prevented translation into the corresponding proteins in normal cells that, in any case, exhibited low levels of gene transcription (43). Some degree of mRNA instability may also exist for HER2 in LNCaP cells since the level of protein expression was lower than expected from the high level observed at mRNA expression. Treatment of PC3 cells with EGF resulted in the phosphorylation of EGF-based receptor dimers such as that including HER2 (i.e. the HER1/HER2 heterodimer) in concordance with previous findings (22,35).

Increasing evidence exists that many substances may stimulate tyrosine phosphorylation of HER molecules leading to recruitment of associated signaling pathways. Thus, the HER family provides critical downstream elements for GPCRs, cytokine receptors, integrins, membrane depolarizing or stress-inducing agents (44,45). Several GPCRs utilize HER transactivation to couple to the ERK/MAPK cascade by mechanisms involving G\textsubscript{i}, G\textsubscript{o}, PKA, protein kinase C (PKC) and other signaling molecules (45,46). This mechanism has been recently reported for VIP in colonic epithelial T84 cells (37). Our results show that this neuropeptide is linked to the HER system at least by two mechanisms since VIP induced the expression of specific genes for HER2 and HER3, but it also stimulated HER2 tyrosine phosphorylation.

VIP stimulated the synthesis of HER2 and HER3 mRNAs and proteins in long time frames compatible with the activation of the classical cyclic AMP/PKA dependent signal cascade and resulting in the expression of mRNA encoding HER2. A related model of activation by luteinizing hormone (LH) of its specific GPCR has been presented in which LH regulates EGF-like growth factors at the transcriptional level and at the level of processing of ligands to their mature forms with subsequent activation of HER/MAPK cascade (45). On the
References


